Windsor Creek Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Windsor Creek Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,786	Closed	-$39K	–	140
2021 Q2	$39K	Hold	14,786	–	–	0.01%	169
2021 Q1	$46K	Buy	+14,786	New	+$53.4K	0.01%	170

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Windsor Creek Advisors's CRVS Position: Q3 2021 in Review

Windsor Creek Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q3 2021, closing a stake of 14,786 shares — an estimated $39K sold.

Windsor Creek Advisors first reported a position in CRVS in Q1 2021 and held it in 2 quarters. The position peaked at $46K in Q1 2021. 61 funds tracked by Wall St. Rank hold CRVS as of Q3 2021.

Windsor Creek Advisors reported no remaining Corvus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Windsor Creek Advisors sold 14,786 Corvus Pharmaceuticals shares in Q3 2021, an estimated $39K.
Windsor Creek Advisors first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 2 quarters.
Windsor Creek Advisors's Corvus Pharmaceuticals position peaked at $46K in Q1 2021.
61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2021.

Based on Windsor Creek Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.